top of page

Granulocyte Colony Stimulating Factor Biosimilars: An Update for Frontline Oncology Practitioners

Thu, Feb 25, 2021 1:00 PM EST


*1.25 CNEs*




Learning objectives:


  • Discuss the current data supporting short- and long-acting granulocyte colony stimulating factor (G-CSF) use in prevention of febrile neutropenia and during the COVID-19 era

  • Formulate practical approaches to incorporating G-CSF biosimilars into healthcare system formularies and/or clinical pathways

  • Recognize the need for educational interventions that will improve healthcare providers’ understanding of G-CSF biosimilars use in cancer supportive care

 
 
 

Comments


Boston_V_color_edited.png

Contact:

Michelle Ranaghan, President

Alissa Gentile, Treasurer

Cameron Keith, Social Media Coordinator

Email: BonsSocialMedia@gmail.com

  • Facebook
  • Instagram
  • LinkedIn
Earthen Media-4.png
bottom of page